1-biphenyl-3-yl-methyl-4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine | 477281-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-biphenyl-3-yl-methyl-4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine
• 英文别名: 1-Biphenyl-3-ylmethyl-4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine；1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[(3-phenylphenyl)methyl]piperazine
• CAS: 477281-29-1
• 化学式: C₂₅H₂₆N₂O₂
• 分子量: 386.494
• InChiKey: XVRGSHVTZMJIAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  24.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-苯基苄基溴 、 eltoprazine hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 1-biphenyl-3-yl-methyl-4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine
  参考文献：
  名称：

  SAR Study of 1-Aryl-4-(phenylarylmethyl)piperazines as Ligands for Both Dopamine D2 and Serotonin 5-HT1A Receptors Showing Varying Degrees of (Ant)agonism. Selection of a Potential Atypical Antipsychotic

  摘要：

  本文描述了多种1-芳基-4-(芳基吡啶甲基)哌嗪（4）的合成及其对多巴胺D2和5-羟色胺1A受体的亲和力。这些化合物在体外和体内均进行了评估，最终确定了候选药物SLV313（4e）具有等效且完全的D2受体拮抗作用和5-HT1A受体激动作用。对SLV313进行细微的结构修改，可以设计出对一个或两个靶标受体具有不同程度部分激动作用的化合物。

  DOI：

  10.1248/cpb.54.1326

文献信息

• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• SAR Study of 1-Aryl-4-(phenylarylmethyl)piperazines as Ligands for Both Dopamine D2 and Serotonin 5-HT1A Receptors Showing Varying Degrees of (Ant)agonism. Selection of a Potential Atypical Antipsychotic
  作者：Roelof Willem Feenstra、Adri van den Hoogenband、Cornelis Nicolaas Jozef Stroomer、Herman Heinrich van Stuivenberg、Martin Theodorus Maria Tulp、Stephen Kenneth Long、Johannes Antonius Maria van der Heyden、Cornelis Gerrit Kruse

  DOI：10.1248/cpb.54.1326

  日期：——

  The syntheses of several 1-aryl-4-(arylpyridylmethyl)piperazines (4) and their affinities for dopamine D2 and serotonin 5-HT1A receptors are described. The compounds were evaluated both in vitro and in vivo, resulting in the identification of the drug candidate SLV313 (4e) with equipotent and full D2 receptor antagonism and 5-HT1A receptor agonism. Minor structural modifications in SLV313 revealed the possibility of designing compounds possessing varying degrees of partial agonism on one or both target receptors.

  本文描述了多种1-芳基-4-(芳基吡啶甲基)哌嗪（4）的合成及其对多巴胺D2和5-羟色胺1A受体的亲和力。这些化合物在体外和体内均进行了评估，最终确定了候选药物SLV313（4e）具有等效且完全的D2受体拮抗作用和5-HT1A受体激动作用。对SLV313进行细微的结构修改，可以设计出对一个或两个靶标受体具有不同程度部分激动作用的化合物。